

DAFTAR PUSTAKA

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int (Suppl)*. 2013;3:1–150.
2. Waziri, B., Duarte, R., & Naicker, S. chronic kidney disease–mineral and bone disorder (CKD-MBD): Current perspectives. 2019; 263–276.
3. Stróżecki, P., Adamowicz, A., Nartowicz, E., et al. PARATHORMON, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. 2001; 23(1); 115–126.
4. Habas E, Eledrisi M, Khan F, Elzouki A-NY. Secondary hyperparathyroidism in chronic kidney disease: Pathophysiology and management. *Cureus*. 2021;
5. Cozzolino, M., Ciceri, P., Volpi, E. M., et al. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease. 2009; 27(4), 338–344.
6. Tejwani, V., & Qian, Q. Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. *Nutrients*. 2013; 5(6), 1913–1936.
7. Cannata-Andia, J. B., & Carrera, F. The pathophysiology of secondary hyperparathyroidism and the consequences of uncontrolled mineral metabolism in chronic kidney disease: The role of cosmos. 1(suppl 1), 2008; i2–i6
8. Carneiro Dias, R. S., José de Araújo Brito, D., Milhomem dos Santos, E., et al. Correlation between parathyroid hormone levels with urinary magnesium excretion in patients with non-dialysis dependent chronic kidney disease. 2020; 341–348.

9. Brown, S. J., Ruppe, M. D., & Tabatabai, L. S. The parathyroid gland and heart disease. 2017; 13(2), 49.
10. Assaad, S. N., El-Aghoury, A. A., El-Sharkawy, et al. Parathormone (PTH) is strongly related to left ventricular mass index (LVMI) in hypertensives, obese, and normal control. 2018; 54(4), 303–306.
11. Suwitra K. Penyakit Ginjal Kronik. In: Setiati S, Alwi I, Sudoyo AW, K. MSi, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. VI. Jakarta. Interna Publishing, 2015. p. 348–57.
12. Indonesian Renal Registry. 10th Report Of Indonesian Renal Registry. 2017. p.1-40
13. Felsenfeld, A. J., Levine, B. S., & Rodriguez, M. Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease 2015; 28(6), 564–577.
14. Kumar, R., & Vallon, V. Reduced renal calcium excretion in the absence of Sclerostin expression. 2014; 25(10), 2159–2168.
15. Kritmetapak, K., & Pongchaiyakul, C. Parathyroid hormone measurement in chronic kidney disease: From basics to clinical implications. 2019; 1–9.
16. Silver, J., & Naveh-Many, T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. 2013; 9(11), 641–649.
17. Kovesdy, C. P., Ahmadzadeh, S., Anderson, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. 2008; 73(11), 1296–1302.

18. Manju, M., Rajendran, S., Mishra, S., & Vithiavathi, S. Correlation of serum calcium, phosphorus and alkaline phosphatase levels with EGFR in newly diagnosed chronic kidney disease patients. 2019; 9(2), 38–43.
19. Kumar, S., Arora, K., Goyal, G., Soin, D., Arora, H., & Garg, C. Correlation of parathyroid hormone levels with mineral status in end-stage renal disease patients. 2018; 22(6), 735.
20. Latus, J., Lehmann, R., Roesel, M., et al. Analysis of α -klotho, fibroblast growth factor-, vitamin-D and calcium-sensing receptor in 70 patients with secondary hyperparathyroidism. 2013; 37(1), 84–94.
21. Wolf, M. Update on fibroblast growth factor 23 in chronic kidney disease. 2012; 82(7), 737–747.
22. Vervloet, M. G., Sezer, S., Massy, Z. A., et al. The role of phosphate in kidney disease. 2016; 13(1), 27–38.
23. Moe, S. M. Rationale to reduce calcium intake in adult patients with chronic kidney disease. 2018; 27(4), 251–257.
24. Gallieni M, Cucciniello E, D'Amato E, et al. Collaborating nephrologists of the CARDIALISI Study Group. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. J Nephrol. 2002; 15(2), 165–70.
25. Ennis, J., Worcester, E., & Coe, F. Contribution of calcium, phosphorus and 25-hydroxyvitamin D to the excessive severity of secondary hyperparathyroidism in African-Americans with CKD. 2012; 27(7), 2847–2853.
26. Rastogi, A., Kumar, S., Kumar, R., et al. Cross-sectional Study of Calcium Phosphate Product and Intact Parathyroid Hormone Levels in Predialysis and

- Postdialysis Patients with Stage 5 Chronic Kidney Disease. 2021;32(4), 967–972.
27. Deger, S. M., Mutluay, R., Derici, U., et al. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?. 2010; 20(1), 85–89.
 28. Voinescu, A., & Martin, K. J. Calcium, phosphate, PTH, vitamin D and FGF-23 in chronic kidney disease. *Nutritional Management of Renal Disease*, Academic press, 2013; 263–283.
 29. Brown E. M. Calcium receptor and regulation of parathyroid hormone secretion. 2000; 1(4), 307–315.
 30. Riccardi, D., & Valenti, G. Localization and function of the renal calcium-sensing receptor. 2016; 12(7), 414–425.
 31. Naves-Diaz, M., Passlick-Deetjen, J., Guinsburg, A., et al. Calcium, phosphorus, pth and death rates in a large sample of dialysis patients from Latin America. the cores study. 2010; 26(6), 1938–1947.
 32. Jean, G., Mayor, B., Hurot, J.-M., et al. Biological impact of targeted dialysate calcium changes in haemodialysis patients: The key role of parathyroid hormone. 2012; 28(1), 176–182.
 33. Tinawi, M. Disorders of calcium metabolism: Hypocalcemia and hypercalcemia. *Cureus*. 2021.
 34. Sah DK, Haque SS, Shah S, Yadav SS. Role of Calcium, Phosphorus and Intact Parathyroid Hormone in Different Stages of Chronic Kidney Disease. 2023; 185